Results 1 to 10 of about 1,675 (195)

Post-Treatment Lyme Disease Syndrome in Six European Countries Using Data from the Burden of Lyme Disease (BOLD) Study [PDF]

Pathogens
Up to 10% of patients with Lyme borreliosis (LB) will experience symptoms that fulfill the Infectious Disease Society of America (IDSA) criteria of post-treatment Lyme disease syndrome (PTLDS).
Holly Yu, Amanda R. Mercadante, Kate Halsby, Alexandra Loew-Baselli, Ye Tan, Frederick J. Angulo, Elizabeth Begier, Mendwas Dzingina, Johan S. Berglund, Anna Moniuszko-Malinowska, Viliam Cibik, Dagmar Zakova, Franc Strle, James H. Stark, on behalf of the BOLD Study Group   +14 more
doaj   +3 more sources

Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review

Antibiotics, 2022
Lyme disease and associated co-infections are increasing worldwide and approximately 20% of individuals develop chronic Lyme disease (CLD)/Post-Treatment Lyme Disease Syndrome (PTLDS) despite early antibiotics.
Phyllis R Freeman, Richard Horowitz
exaly   +4 more sources

Protein biomarker profiles in serum and CSF in 158 patients with PTLDS or persistent symptoms after presumed tick-bite exposure compared to those in patients with confirmed acute neuroborreliosis

PLoS ONE, 2022
BackgroundCurrent diagnostics for patients with lingering symptoms categorized as post-treatment Lyme disease syndrome (PTLDS) have their limitations and may be difficult to interpret.
Andreas Mårtensson, Kenneth Nilsson, Marie Edvinsson   +2 more
exaly   +3 more sources

Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review

Antibiotics, 2020
Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double-dose dapsone combination therapy (DDD CT) for a total of 7–8 weeks. At the completion
Phyllis R Freeman, Richard Horowitz
exaly   +4 more sources

Evaluation of immunoreactive epitopes in the sera and cerebrospinal fluid of patients with post-treatment Lyme disease syndrome [PDF]

Scientific Reports
While most patients fully recover after treatment for Lyme disease with recommended antibiotic regimens, some report non-specific symptoms after treatment. When these symptoms are unexplained by other conditions and persist for ≥ 6 months, this condition
Adriana R. Marques, Santiago Sanchez-Vicente, Akash Nagapurkar, Aleah Eschman, Siu Ping Ng, W. Ian Lipkin, Rafal Tokarz   +6 more
doaj   +2 more sources

Patient roadmap and economic burden of chronic tick-borne illness and post-treatment Lyme disease syndrome in Ireland, and public health issues arising [PDF]

Frontiers in Public Health
Lyme borreliosis (LB), commonly referred to as Lyme disease (LD), is a prominent global health issue, exhibiting a seroprevalence rate of 14.5%. Heightened incidence levels of LD have been recorded in parts of Europe, Poland, Eastern Europe, and the ...
Gordana Avramovic, Gordana Avramovic, Leona Gilbert, Sławomir Kujawski, Sigrid Blehle, Pascal Jollivet-Courtois, Paweł Zalewski, Paweł Zalewski, Nabin Adhikari, Kunal Garg, John Shearer Lambert, John Shearer Lambert   +11 more
doaj   +2 more sources

Bioinformatics analysis of potential molecular markers and immunological characteristics shared between post-treatment Lyme disease syndrome and rheumatoid arthritis [PDF]

Frontiers in Immunology
BackgroundPost-treatment Lyme disease syndrome (PTLDS) and rheumatoid arthritis (RA) are both characterized by chronic inflammation and immune dysregulation; however, whether they share underlying molecular immune mechanisms remains unclear ...
Yantong Chen, Xin Guo, Xinyuan Xu, Meng Liu, Yanshuang Luo, Shunli Cai, Huangjuan Zhao, Yan Dong, Yan Dong, Guozhong Zhou, Guozhong Zhou   +10 more
doaj   +2 more sources

Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies [PDF]

Blood Advances
: Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment.
Suheil Albert Atallah-Yunes, Arushi Khurana, Thomas M. Habermann   +2 more
doaj   +2 more sources

Evidence-domain translation in the Lyme disease controversy over persistent post-treatment symptoms [PDF]

Frontiers in Cellular and Infection Microbiology
The debate between post-treatment Lyme disease syndrome (PTLDS) and chronic Lyme disease (CLD) reflects different views about the causes and treatment of persistent symptoms attributed to Lyme disease, including symptoms that continue after recommended ...
Teo Susnjak, Lorenz Brehme, Kunal Garg, Gordana Avramovic, Gordana Avramovic, Leona Gilbert   +5 more
doaj   +2 more sources

A comparison of genome-wide association analyses of persistent symptoms after Lyme disease, fibromyalgia, and myalgic encephalomyelitis – chronic fatigue syndrome [PDF]

BMC Infectious Diseases
Background Up to 20% of Lyme disease cases experience post-treatment Lyme disease syndrome (PTLDS). The biological basis for PTLDS is poorly understood and no evidence-based treatment has been identified.
Annemarie G. Hirsch, Anne E. Justice, Amy Poissant, Cara M. Nordberg, Navya S. Josyula, John Aucott, Alison W. Rebman, Brian S. Schwartz   +7 more
doaj   +2 more sources